MYOLIVITY
DEAD

Serial Number

90726719

Owner

Sarepta Therapeutics, Inc.

Attorney

Maury M. Tepper, III

Filing Date

May 21, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MYOLIVITY Trademark

Serial Number: 90726719

MYOLIVITY is a trademark filed by Sarepta Therapeutics, Inc. on May 21, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Sarepta Therapeutics, Inc.

Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

May 21, 2021

Registration Date

Not Registered

Published for Opposition

August 30, 2022

Goods & Services

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products, namely, pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 1, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 1, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 23, 2025 EXRA
SOU EXTENSION 5 GRANTED
Jul 23, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 23, 2025 AITU
SOU TEAS EXTENSION RECEIVED
Apr 7, 2025 EEXT
SOU EXTENSION 5 FILED
Apr 6, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 22, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 22, 2024 EX4G
SOU EXTENSION 4 FILED
Oct 22, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 22, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 29, 2024 EXRA
SOU EXTENSION 3 GRANTED
Mar 28, 2024 EX3G
SOU EXTENSION 3 FILED
Mar 28, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 28, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 12, 2023 EXRA
SOU EXTENSION 2 GRANTED
Oct 10, 2023 EX2G
SOU EXTENSION 2 FILED
Oct 10, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 10, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 30, 2023 EXRA
SOU EXTENSION 1 GRANTED
Mar 28, 2023 EX1G
SOU EXTENSION 1 FILED
Mar 28, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 28, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 25, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 30, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 30, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 10, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 26, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 25, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 25, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 25, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 3, 2022 GNRN
NON-FINAL ACTION E-MAILED
Feb 3, 2022 GNRT
NON-FINAL ACTION WRITTEN
Feb 3, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 2, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 18, 2021 NWOS
NEW APPLICATION ENTERED
May 25, 2021 NWAP